Adverse effects (side effects; treatment withdrawals) · patients with hypertension
1 finding from 1 review
Total mortality Duration: 1 to 5 years · patients with hypertension
First‐line thiazides showed no clear difference in total mortality Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Total serious adverse events Duration: 1.75 to 3 years · patients with hypertension
First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).
1 finding from 1 review
Total mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower non‐fatal cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Major bleedinga · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin leads to higher major bleedinga compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower all cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with ACE inhibitor (low certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs may leads to lower stroke compared with ACE inhibitor (low certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ACE inhibitor (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs probably leads to lower myocardial infarction compared with ARB (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with ARB (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ARB (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with diuretic (moderate certainty).
1 finding from 1 review